FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

								· ,												
Name and Address of Reporting Person*     Hunt Hazel						2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [ CORT ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (spec					
l	`	First) ERAPEUTICS	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 09/28/2022									X Officer (give title below) below below Chief Scientific Office				, poonly	
149 COMMONWEALTH DRIVE						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable					
(Street) MENLO	PARK C	A	94025		-								Lin	X Form f						
(City)	()	·	(Zip)																	
		Tab	le I - Nor	n-Deriv	/ativ	e Se	curit	ties Ac	quire	d, Di	spos	ed o	f, or Bei	neficial	ly Owned	ı				
Date					Day/Year) i		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr. 5)		ecuriti posed	ies Acquire Of (D) (Insi	ed (A) or tr. 3, 4 and	Benefici Owned	es For ally (D) Following (I) (		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Cod	e V	Am	ount	(A) or (D)	Price	Transac	Reported Transaction(s) (Instr. 3 and 4)			(111301. 4)	
Common Stock 09/28				8/202	/2022			M		5	50,000		\$2.0	8 103	103,143		D			
Common Stock 09/2				09/28	8/2022				F <sup>(1</sup>		2	29,997 D \$		\$26.0	4 73,146			D		
		-	Table II - I										or Bene de secu		Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Date,	4. Transaction Code (Instr. 8)		n of		Expira	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exerci	sable	Expira Date		Title	Amount or Number of Shares						
Stock option (right to	\$2.08	09/28/2022			М			50,000	(2		01/30/	2023	Common Stock	50,000	\$0.00	0		D		

## **Explanation of Responses:**

1. These shares were withheld so the Reporting Person could satisfy the exercise price and the withholding of taxes arising from a net (cashless) exercise of stock options. The options subject to the net exercise were to expire on January 30, 2023.

2. Fully exercisable.

## Remarks:

The power of attorney under which this form was signed is on file with the Commission.

/s/ Joseph Douglas Lyon, as attorney-in-fact for Hazel Hunt

09/30/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.